HanAll Biopharma said Monday it has presented phase 2 clinical trial results for HL036, a dry eye treatment, at the Ophthalmology Innovation Summit at American Academy of Ophthalmology 2018 (OIS@AAO 2018).

OIS@AAO 2018 is an ophthalmologic conference participated by participants and investors involved in eye diseases and related medical equipment. HL036 is a biopharmaceutical that inhibits tumor necrosis factor (TNF).

The results presented contained HanAll Biopharma’s phase 2 clinical trials, in which the company confirmed the efficacy and safety of HL036 in 150 patients with dry eye syndrome.

With the completion of phase 2 clinical trials, the company, a subsidiary of Daewoong Pharmaceuticals, plans to go ahead with phase 3 clinical trials early next year.

“At the conference, we demonstrated the safety and efficacy of HL036 in inhibiting corneal damage and relieving dry eye syndrome confirmed in the U.S. phase 2 clinical trials,” HanAll Biopharma’s Medical Director Edward Bernton said. “We plan to advertise the superior clinical effects of the HL036 eye drops to major pharmaceutical and investors in the ophthalmic field.”

At the same time, the company will conduct a clinical trial differentiated from competitors, Professor Bernton added.